Background Recent clinical results 1 provide a rationale for cancer immunotherapy based on activation of “ anti-regulatory ” T cells. Anti-regulatory T cells recognize antigens expressed by immunosuppressive cells and thereby target pro-inflammatory signals to the tumor microenvironment. 2 TGFB1 promotes immune suppression in diverse cancers. We hypothesize that activating T cells against TGFB1 may allow targeting of pro-inflammatory immune response to TGFB1-expressing tumors while avoiding the toxicities associated with TGFB1 pan-inhib-ition. TGFB1-specific T cells are frequently detected in humans. 3 Vaccination with a TGFB1 peptide ameliorates fibrosis in a model of chronic colitis 4 and enhances the anti-tumor activity of an HPV16 E7-specific vaccine 5 , indicating a therapeutic potential of a TGFB1 vaccine. Here we sought to enhance the specificity anti-TGFB1 immune responses and identify peptides with high TGFB1 selectivity (vs TGFB2/3), thereby mitigating potential off-target toxicities. To understand the TGFB1 landscape in human tumors we performed a mul-tiplexed IHC analysis of TGFB1 expression on tumor cells and the multiplicity of cells in the tumor microenvironment. Methods PBMCs were assayed by ELISPOT to measure responses to peptides from TGFB1, TGFB2, and TGFB3. TGFB1 expression was examined by multiplex immunofluores-cence in a tissue microarray panel of tumor indications with hyperplexed visualization of markers on a single section. Vaccination is evaluated in mouse models expressing TGFb1. Tumor growth monitored, organs and tumor samples collected.

/pdf/1182-modulating-the-tumor-microenvironment-by-a-targeting-us2ww6vl.pdf

1182 Modulating the tumor microenvironment by a targeting TGFB1 with vaccine-induced immune responses

<h3>Background</h3> Arginase-1 (ARG1) regulates tumor cells immune escape through various mechanisms in the tumor microenvironment (TME) and is being targeted experimentally in the clinic. However, selective and efficacious inhibitors of ARG1 remain elusive. Vaccination against TME targets have shown to be an exciting therapeutic approach where an IDO1/PD-L1 dual vaccine has shown substantial activity in early trials in melanoma<sup>1</sup> (and confirmatory Ph3 trial underway NCT05155254). We previously showed that vaccination against ARG1 increases anti-tumor activity preclinically.<sup>2</sup> Here we set out to develop a biological rationale for an ARG1 vaccine as a monotherapy or in combination with other immune therapies and understand the underlying mode of action of the treatment. <h3>Methods</h3> ARG1 expression was examined by multiplex immunofluorescence in a tumor microarray (TMA) panel of cancer indications with a hyperplexed visualization of multiple markers on a single section. Vaccination was evaluated in mouse models expressing ARG1. Mice were inoculated with tumor cells and treated with ARG1 peptides. Tumor growth was monitored, organs and tumor samples were collected. Histopathological examination was performed on multiple tissues. Vaccine activity was determined per IFNgamma Elispot assay on splenocytes. Tumor samples were processed, RNA sequencing and flow cytometry analysis of the immune infiltrate were conducted. <h3>Results</h3> The TMA analysis confirmed ARG1 expression in the TME and revealed that a distinct immune suppressive population of cells in the TME expresses it independently of IDO1/PD-L1 providing a rationale for combining the vaccines. ARG1 surrogate peptides of 20 amino acids (ARG1<sub>261-280</sub>, ARG1<sub>191-210</sub>) were identified and selected based on the induction of ARG1-specific IFNgamma recall responses in BALB/c or C57BL/6 animals. Both peptides demonstrated anti-tumor activity in vivo. This was associated with increased infiltration of CD45+cells, CD3+ and CD4+ T-cells at tumor site. The anti-tumor effect was enhanced when ARG1 treatment was combined with anti-PD-1 mAb, and/or in combination with a the dual IDO1/PD-L1 vaccine. Detailed efficacy results in the models will be discussed in addition to the cellular and molecular analysis of the tumors in the various cohorts and treatments elucidating the mode of action of the treatment. <h3>Conclusions</h3> ARG1 is an attractive TME target and vaccination against it drove efficacy in vivo by increasing the recruitment of immune cells at tumor site thus changing from an immunosuppressive to a pro-inflammatory microenvironment. These data support the preclinical development of an ARG1 vaccine for the treatment of multiple solid tumors. <h3>References</h3> Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nat Med</i> 2021 Dec;<b>27</b>(12):2212-2223. Aaboe Jørgensen M, Ugel S, Linder Hübbe M, Carretta M, Perez-Penco M, Weis-Banke SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, De Sanctis F, Frusteri C, Iezzi M, Zocca MB, Hargbøll Madsen D, Wakatsuki Pedersen A, Bronte V, Andersen MH. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade. <i>Cancer Immunol Res</i>. 2021 Nov;<b>9</b>(11):1316-1326. <h3>Ethics Approval</h3> All animal experiments were reviewed and approved by the Danish Animal Experimentation Council and performed under license number 2018-15-0201-01395. 

/pdf/1440-arginase-1-peptide-based-vaccine-is-an-exciting-2osx6itx.pdf

1440 Arginase-1 peptide-based vaccine is an exciting approach to modulate the tumor microenvironment and drive efficacy in preclinical tumor models

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

Brian Weinert

Author Tools

Chat about Author

Papers

1182 Modulating the tumor microenvironment by a targeting TGFB1 with vaccine-induced immune responses

1440 Arginase-1 peptide-based vaccine is an exciting approach to modulate the tumor microenvironment and drive efficacy in preclinical tumor models